About Avalo Therapeutics
Avalo Therapeutics is a publicly listed company based in Wayne (United States) founded in 2011. Therapeutics for rare and immunological diseases are developed. The company has 23 employees. Avalo Therapeutics has completed 1 acquisition, including AlmataBio. Its chief executive, as recorded, is Garry A Neil. Avalo Therapeutics offers products and services including AVTX-009, quisovalimab, and AVTX-008. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its legal entity is Avalo Therapeutics, Inc. Its competitors include Biogen, ADMA Biologics and Kymeratx; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2011 and based in Wayne, United States, focus is placed on the development of therapeutics targeting rare and immunological diseases. The product pipeline includes AVTX-002, an anti-LIGHT monoclonal antibody used for acute respiratory distress syndrome, inflammatory bowel disease, and non-eosinophilic asthma. Additional candidates such as AVTX-006, AVTX-801, and AVTX-802 address lymphatic malformations and congenital disorders of glycosylation within the biotechnology sector.
- Headquarters Wayne, United States
- Employees 23
- Stage Public
- SectorsHealthcare
- Phoneβ’β’β’β’ β’β’β’β’
- Website avalotx.com
- Social LinkedIn X
- Legal Name Avalo Therapeutics, Inc.
Products & Services of Avalo Therapeutics
Avalo Therapeutics offers a comprehensive portfolio of products and services, including AVTX-009, quisovalimab, and AVTX-008.
Targets inflammatory diseases via anti-IL-1β therapy for immune disorders.
Anti-LIGHT mAb designed for treating immune dysregulation conditions.
BTLA agonist protein for regulating immune responses in diseases.
Funding Insights of Avalo Therapeutics
- Total Rounds 3
- Last Round Post-IPO β $69.4M
- First Round $292,476
(Aug 2011)
- Investors Count 8
All 3 funding rounds of Avalo Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | $69.4M | Post-IPO | β | Commodore Capital, TCG Crossover | |
| May 2016 | $1.02M | Grant | β | β | |
| Aug 2011 | $292,476 | Grant | β | β |
8 investors in total: 8 institutional.
Investors in Avalo Therapeutics
Avalo Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Orbimed and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is provided to healthcare startups by Commodore Capital. | commodorecapital.com | New York, United States | ||
| tcgcrossover.com | ||||
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Deep Track Capital is engaged in biotechnology investment activities. | deeptrackcapital.com | Greenwich, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Multiple industries are operated across by the diversified conglomerate Petrichor. | 2014 | petrichor.io | Reno, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Avalo Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Avalo Therapeutics
1 people are tracked at Avalo Therapeutics (1 in leadership); the tracked headcount is 23.
| Name | Role | Group |
|---|---|---|
Garry A Neil | CEO | Leadership |
Complete people profiles for Avalo Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Avalo Therapeutics
Avalo Therapeutics is a publicly listed company on the NASDAQ with ticker symbol AVTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Oct 2015
- Listed onNASDAQ: AVTX
- Listed entityAvalo Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS05338F3064
- Share price$12.01 (-9.29% on the day) · 2026-10-13
- Market capitalisation$644.1M
- EPS (diluted, trailing year)$-4.74
- Volume (last session)1,649,096
Financials of Avalo Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $59,000 | -$78.3M | -$72.6M |
| 2024 | $441,000 | -$35.1M | -$40.7M |
| 2023 | $1.9M | -$31.5M | -$23.3M |
| 2022 | $18.1M | -$41.7M | -$37.3M |
| 2021 | $5.4M | -$84.3M | -$80.5M |
Detailed financial statements for Avalo Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Avalo Therapeutics
Avalo Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AlmataBio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Biotechnology initiatives are pursued by AlmataBio in the United States. | almatabio.com | Georgiana, United States | 2023 | Mar 2024 | β’β’β’β’ |
Complete acquisition details for Avalo Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Avalo Therapeutics
5 dated milestones of Avalo Therapeutics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Avalo Therapeutics is founded.
- Funding First funding round of $292K.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires AlmataBio.
- Funding Latest funding round, Post-IPO, of $69.4M.
Competitors of Avalo Therapeutics
Avalo Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, ADMA Biologics and Kymeratx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. |
Detailed competitors of Avalo Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Avalo Therapeutics
The website of Avalo Therapeutics (avalotx.com) receives about 4.8K visits a month.
- Monthly visits4.8K
▼ 13.2% vs previous month
Websites whose visitors overlap most with Avalo Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
scionlifesciences.com | scionlifesciences.com | 100% | #9,488,997 | β | |
| exegipharma.com | 94% | 2.1K | #7,496,544 | View details | |
| taslyus.com | 81% | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Avalo Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Avalo Therapeutics
Complete news archive for Avalo Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avalo Therapeutics
Avalo Therapeutics was founded in 2011.
Avalo Therapeutics is headquartered in Wayne, United States.
Garry A Neil is the CEO of Avalo Therapeutics, as recorded in our data.
Avalo Therapeutics has 23 employees.
Annual revenue of Avalo Therapeutics is $59K as on Dec 31, 2025.
Founded in 2011 and based in Wayne, United States, focus is placed on the development of therapeutics targeting rare and immunological diseases. The product pipeline includes AVTX-002, an anti-LIGHT monoclonal antibody used for acute respiratory distress syndrome, inflammatory bowel disease, and non-eosinophilic asthma. Additional candidates such as AVTX-006, AVTX-801, and AVTX-802 address lymphatic malformations and congenital disorders of glycosylation within the biotechnology sector.
Avalo Therapeutics's top competitors include ADMA Biologics, Kymeratx and Biogen.
Avalo Therapeutics offers AVTX-009, quisovalimab, and AVTX-008.
Yes, Avalo Therapeutics is publicly traded on NASDAQ under the ticker symbol AVTX.
Avalo Therapeutics has made 1 acquisition, including AlmataBio.
Avalo Therapeutics has 8 investors. Key investors include HHS, Orbimed, RA Capital, Petrichor, and Commodore Capital.
Avalo Therapeutics operates through Avalo Therapeutics, Inc..